Merck kills Tredaptive worldwide
This article was originally published in Scrip
Merck & Co is withdrawing its troubled dyslipidemia drug Tredaptive (niacin plus laropiprant) in all markets where it is available. The decision comes the same day that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee decided that the product's risks outweighed its benefits and recommended its suspension.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.